

Robert P Baughman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6490735/publications.pdf>

Version: 2024-02-01

191
papers

13,590
citations

23544

58
h-index

24232

110
g-index

195
all docs

195
docs citations

195
times ranked

7995
citing authors

#	ARTICLE	IF	CITATIONS
1	An Official American Thoracic Society Clinical Practice Guideline: The Clinical Utility of Bronchoalveolar Lavage Cellular Analysis in Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 1004-1014.	2.5	832
2	Sarcoidosis. Lancet, The, 2003, 361, 1111-1118.	6.3	682
3	Infliximab Therapy in Patients with Chronic Sarcoidosis and Pulmonary Involvement. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 795-802.	2.5	629
4	Pulmonary sarcoidosis. Lancet Respiratory Medicine, the, 2018, 6, 389-402.	5.2	544
5	Utility of a Lung Biopsy for the Diagnosis of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 193-196.	2.5	525
6	Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2020, 201, e26-e51.	2.5	521
7	A Concise Review of Pulmonary Sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 573-581.	2.5	426
8	An anatomical study of cholinergic innervation in rat cerebral cortex. Neuroscience, 1988, 25, 457-474.	1.1	391
9	Two types of cholinergic innervation in cortex, one co-localized with vasoactive intestinal polypeptide. Nature, 1984, 309, 153-155.	13.7	362
10	The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2014, 31, 19-27.	0.2	273
11	Sarcoidosis in America. Analysis Based on Health Care Use. Annals of the American Thoracic Society, 2016, 13, 1244-1252.	1.5	257
12	ERS clinical practice guidelines on treatment of sarcoidosis. European Respiratory Journal, 2021, 58, 2004079.	3.1	248
13	Definition and Consensus Diagnostic Criteria for Neurosarcoidosis. JAMA Neurology, 2018, 75, 1546.	4.5	247
14	PD-1 up-regulation on CD4 ⁺ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF- β 1 production. Science Translational Medicine, 2018, 10, .	5.8	225
15	Survival in Sarcoidosis-Associated Pulmonary Hypertension. Chest, 2010, 138, 1078-1085.	0.4	213
16	Thalidomide for Chronic Sarcoidosis. Chest, 2002, 122, 227-232.	0.4	202
17	Biochemical characterization and cellular localization of the cholinergic system in the chicken retina. Brain Research, 1977, 138, 469-485.	1.1	188
18	Cholinergic neuropil of the striatum observes striosomal boundaries. Nature, 1986, 323, 625-627.	13.7	178

#	ARTICLE	IF	CITATIONS
19	Six-Minute Walk Test and Health Status Assessment in Sarcoidosis. <i>Chest</i> , 2007, 132, 207-213.	0.4	178
20	Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. <i>European Respiratory Journal</i> , 2014, 44, 1296-1307.	3.1	177
21	Racial Difference in Sarcoidosis Mortality in the United States. <i>Chest</i> , 2015, 147, 438-449.	0.4	174
22	Both NMDA and non-NMDA subtypes of glutamate receptors are concentrated at synapses on cerebral cortical neurons in culture. <i>Neuron</i> , 1991, 7, 593-603.	3.8	170
23	Treatment of Sarcoidosis. <i>Clinics in Chest Medicine</i> , 2008, 29, 533-548.	0.8	165
24	Secondary vestibular cholinergic projection to the cerebellum of rabbit and rat as revealed by choline acetyltransferase immunohistochemistry, retrograde and orthograde tracers. <i>Journal of Comparative Neurology</i> , 1992, 317, 250-270.	0.9	152
25	Predictors of Mortality in Pulmonary Sarcoidosis. <i>Chest</i> , 2018, 153, 105-113.	0.4	152
26	Bosentan for Sarcoidosis-Associated Pulmonary Hypertension. <i>Chest</i> , 2014, 145, 810-817.	0.4	144
27	Challenges in Cardiac and Pulmonary Sarcoidosis. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1878-1901.	1.2	119
28	Cholinergic innervation of the cerebellum of rat, rabbit, cat, and monkey as revealed by choline acetyltransferase activity and immunohistochemistry. <i>Journal of Comparative Neurology</i> , 1992, 317, 233-249.	0.9	118
29	Agent Orange and the Vietnamese: the persistence of elevated dioxin levels in human tissues.. <i>American Journal of Public Health</i> , 1995, 85, 516-522.	1.5	116
30	Technical Aspects of Bronchoalveolar Lavage: Recommendations for a Standard Procedure. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2007, 28, 475-485.	0.8	116
31	New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches. <i>Lancet Respiratory Medicine</i> , 2015, 3, 813-822.	5.2	110
32	Aspartate and glutamate as possible neurotransmitters of cells in layer 6 of the visual cortex. <i>Nature</i> , 1980, 287, 848-850.	13.7	109
33	Established and experimental medical therapy of pulmonary sarcoidosis. <i>European Respiratory Journal</i> , 2013, 41, 1424-1438.	3.1	109
34	Vestibular primary afferent projection to the cerebellum of the rabbit. <i>Journal of Comparative Neurology</i> , 1993, 327, 521-534.	0.9	107
35	RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF INFliximab IN PATIENTS WITH CHRONIC PULMONARY SARCOIDOSIS. <i>Chest</i> , 2005, 128, 202S.	0.4	106
36	Significant CD4, CD8, and CD19 Lymphopenia in Peripheral Blood of Sarcoidosis Patients Correlates with Severe Disease Manifestations. <i>PLoS ONE</i> , 2010, 5, e9088.	1.1	105

#	ARTICLE	IF	CITATIONS
37	Changes in Chest Roentgenogram of Sarcoidosis Patients During a Clinical Trial of Infliximab Therapy. <i>Chest</i> , 2009, 136, 526-535.	0.4	98
38	Liver-test abnormalities in sarcoidosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 17-24.	0.8	97
39	Binding of CXCL8/IL-8 to <i>Mycobacterium tuberculosis</i> Modulates the Innate Immune Response. <i>Mediators of Inflammation</i> , 2015, 2015, 1-11.	1.4	96
40	Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis. <i>European Respiratory Review</i> , 2020, 29, 190146.	3.0	92
41	Distinct Muscarinic Receptor Subtypes Suppress Excitatory and Inhibitory Synaptic Responses in Cortical Neurons. <i>Journal of Neurophysiology</i> , 1997, 77, 709-716.	0.9	90
42	Pulmonary sarcoidosis. <i>Clinics in Chest Medicine</i> , 2004, 25, 521-530.	0.8	89
43	Cardiac Sarcoidosis. <i>Chest</i> , 2017, 151, 139-148.	0.4	85
44	Ocular Sarcoidosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2010, 31, 452-462.	0.8	84
45	Evidence-based therapy for cutaneous sarcoidosis. <i>Clinics in Dermatology</i> , 2007, 25, 334-340.	0.8	80
46	Treatment of Sarcoidosis. <i>Clinical Reviews in Allergy and Immunology</i> , 2015, 49, 79-92.	2.9	78
47	Pulmonary hypertension in sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2006, 23, 108-116.	0.2	78
48	Tumour Necrosis Factor in Sarcoidosis and its Potential for Targeted Therapy. <i>BioDrugs</i> , 2003, 17, 425-431.	2.2	77
49	Clinical characteristics of patients with bone sarcoidosis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 143-148.	1.6	76
50	Repository corticotropin for Chronic Pulmonary Sarcoidosis. <i>Lung</i> , 2017, 195, 313-322.	1.4	75
51	Intrastriatal grafts derived from fetal striatal primordia: II. Reconstitution of cholinergic and dopaminergic systems. <i>Journal of Comparative Neurology</i> , 1990, 295, 1-14.	0.9	69
52	Management of neurosarcoidosis: a clinical challenge. <i>Current Opinion in Neurology</i> , 2019, 32, 475-483.	1.8	67
53	Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry. <i>European Respiratory Journal</i> , 2020, 55, 1901747.	3.1	67
54	Chronic pulmonary aspergillosis complicating sarcoidosis. <i>European Respiratory Journal</i> , 2017, 49, 1602396.	3.1	66

#	ARTICLE	IF	CITATIONS
55	Treatment of sarcoidosis: grading the evidence. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 677-687.	1.3	66
56	Therapy for sarcoidosis: evidence-based recommendations. <i>Expert Review of Clinical Immunology</i> , 2012, 8, 95-103.	1.3	64
57	Upper airway.4: Sarcoidosis of the upper respiratory tract (SURT). <i>Thorax</i> , 2010, 65, 181-186.	2.7	63
58	Ventilator-Associated Pneumonia Patients who Do Not Reduce Bacteria from the Lungs have a Worse Prognosis. <i>Journal of Intensive Care Medicine</i> , 2003, 18, 269-274.	1.3	62
59	A retrospective pilot study examining the use of Acthar gel in sarcoidosis patients. <i>Respiratory Medicine</i> , 2016, 110, 66-72.	1.3	62
60	Pulmonary Hypertension in Sarcoidosis. <i>Clinics in Chest Medicine</i> , 2015, 36, 703-714.	0.8	61
61	Role of Liver Function Tests in Detecting Methotrexate-Induced Liver Damage in Sarcoidosis. <i>Archives of Internal Medicine</i> , 2003, 163, 615.	4.3	60
62	Frequency of acute worsening events in fibrotic pulmonary sarcoidosis patients. <i>Respiratory Medicine</i> , 2013, 107, 2009-2013.	1.3	58
63	Nicotine Treatment Improves Toll-Like Receptor 2 and Toll-Like Receptor 9 Responsiveness in Active Pulmonary Sarcoidosis. <i>Chest</i> , 2013, 143, 461-470.	0.4	58
64	Income and Other Contributors to Poor Outcomes in U.S. Patients with Sarcoidosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 955-964.	2.5	57
65	Clinical features of sarcoidosis associated pulmonary hypertension: Results of a multi-national registry. <i>Respiratory Medicine</i> , 2018, 139, 72-78.	1.3	55
66	Use of fluticasone in acute symptomatic pulmonary sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2002, 19, 198-204.	0.2	54
67	Therapeutic options for sarcoidosis: new and old. <i>Current Opinion in Pulmonary Medicine</i> , 2002, 8, 464-469.	1.2	52
68	Closure Operators and Lattice Extensions. <i>Order</i> , 2004, 21, 43-48.	0.3	51
69	The Use of Carbapenems in the Treatment of Serious Infections. <i>Journal of Intensive Care Medicine</i> , 2009, 24, 230-241.	1.3	48
70	Chronic Facial Sarcoidosis Including Lupus Pernio. <i>American Journal of Clinical Dermatology</i> , 2008, 9, 155-161.	3.3	45
71	Pulmonary manifestations of sarcoidosis. <i>Presse Medicale</i> , 2012, 41, e289-e302.	0.8	45
72	Dendritic domains of medium spiny neurons in the primate striatum: Relationships to striosomal borders. <i>Journal of Comparative Neurology</i> , 1993, 337, 614-628.	0.9	44

#	ARTICLE	IF	CITATIONS
73	Six-minute walk test in managing and monitoring sarcoidosis patients. <i>Current Opinion in Pulmonary Medicine</i> , 2007, 13, 439-444.	1.2	43
74	Refractory Pulmonary Sarcoidosis. <i>Clinical Pulmonary Medicine</i> , 2016, 23, 67-75.	0.3	43
75	Pulmonary hypertension associated with sarcoidosis. <i>Arthritis Research and Therapy</i> , 2007, 9, S8.	1.6	42
76	Relapses of sarcoidosis: what are they and can we predict who will get them?. <i>European Respiratory Journal</i> , 2014, 43, 337-339.	3.1	41
77	Sarcoidosis: patient treatment priorities. <i>ERJ Open Research</i> , 2018, 4, 00141-2018.	1.1	41
78	Sarcoidosis Diagnostic Score. <i>Chest</i> , 2018, 154, 1052-1060.	0.4	41
79	Safety of performing transbronchial lung cryobiopsy on hospitalized patients with interstitial lung disease. <i>Respiratory Medicine</i> , 2018, 140, 71-76.	1.3	40
80	Advanced sarcoidosis. <i>Current Opinion in Pulmonary Medicine</i> , 2019, 25, 497-504.	1.2	40
81	The potential additional benefit of infliximab in patients with chronic pulmonary sarcoidosis already receiving corticosteroids: A retrospective analysis from a randomized clinical trial. <i>Respiratory Medicine</i> , 2014, 108, 189-194.	1.3	39
82	GABAergic Transcallosal Neurons in Developing Rat Neocortex. <i>European Journal of Neuroscience</i> , 1997, 9, 1137-1143.	1.2	38
83	Biologic therapies in the treatment of sarcoidosis. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 817-825.	1.3	38
84	Sarcoidosis: an update on current pharmacotherapy options and future directions. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2431-2448.	0.9	37
85	Sarcoidosis Involving the Gastrointestinal Tract: Diagnostic and Therapeutic Management. <i>American Journal of Gastroenterology</i> , 2019, 114, 1238-1247.	0.2	36
86	When the Game Changes. <i>Chest</i> , 2020, 158, 892-895.	0.4	36
87	Partitioning of 2,3,7,8-chlorinated dibenzo-p-dioxins and dibenzofurans between adipose tissue and plasma lipid of 20 Massachusetts Vietnam veterans. <i>Chemosphere</i> , 1990, 20, 951-958.	4.2	35
88	Newer Therapies for Cutaneous Sarcoidosis. <i>American Journal of Clinical Dermatology</i> , 2004, 5, 385-394.	3.3	35
89	Different time course of development for high-affinity choline uptake and choline acetyltransferase in the chick retina. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1978, 75, 2525-2529.	3.3	33
90	The complimentary role of transbronchial lung cryobiopsy and endobronchial ultrasound fine needle aspiration in the diagnosis of sarcoidosis. <i>Respiratory Medicine</i> , 2017, 131, 65-69.	1.3	33

#	ARTICLE	IF	CITATIONS
91	Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation. <i>European Journal of Cancer</i> , 2021, 158, 208-216.	1.3	33
92	Cholinergic Innervation of the Cerebellum of the Rat by Secondary Vestibular Afferents. <i>Annals of the New York Academy of Sciences</i> , 1992, 656, 566-579.	1.8	30
93	Medical Therapy of Sarcoidosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2014, 35, 391-406.	0.8	30
94	Health-Related Quality of Life (HRQoL) in Sarcoidosis: Diagnosis, Management, and Health Outcomes. <i>Diagnostics</i> , 2021, 11, 1089.	1.3	30
95	Sarcoidosis-Associated Pulmonary Hypertension. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017, 38, 450-462.	0.8	29
96	Endobronchial ultrasound-guided transbronchial needle aspiration in sarcoidosis: Beyond the diagnostic yield. <i>Respirology</i> , 2019, 24, 531-542.	1.3	28
97	WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension. <i>European Respiratory Review</i> , 2022, 31, 210165.	3.0	28
98	Choline acetyltransferase immunocytochemistry of Edinger-Westphal and ciliary ganglion afferent neurons in the cat. <i>Brain Research</i> , 1987, 423, 293-304.	1.1	27
99	Diagnosis of ventilator-associated pneumonia. <i>Current Opinion in Critical Care</i> , 2003, 9, 397-402.	1.6	25
100	Clinical phenotyping: role in treatment decisions in sarcoidosis. <i>European Respiratory Review</i> , 2020, 29, 190145.	3.0	25
101	Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2016, 32, 289-95.	0.2	25
102	Current concepts regarding calcium metabolism and bone health in sarcoidosis. <i>Current Opinion in Pulmonary Medicine</i> , 2017, 23, 476-481.	1.2	24
103	Short-Term Particulate Air Pollution Exposure is Associated with Increased Severity of Respiratory and Quality of Life Symptoms in Patients with Fibrotic Sarcoidosis. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 1077.	1.2	24
104	How the Frequency and Phenotype of Sarcoidosis is Driven by Environmental Determinants. <i>Lung</i> , 2019, 197, 427-436.	1.4	24
105	Riociguat for Sarcoidosis-Associated Pulmonary Hypertension. <i>Chest</i> , 2022, 161, 448-457.	0.4	24
106	The impact of demographic disparities in the presentation of sarcoidosis: A multicenter prospective study. <i>Respiratory Medicine</i> , 2021, 187, 106564.	1.3	24
107	Phase II Investigation of the Efficacy of Antimycobacterial Therapy in Chronic Pulmonary Sarcoidosis. <i>Chest</i> , 2021, 159, 1902-1912.	0.4	23
108	Novel Therapies for Sarcoidosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2007, 28, 128-133.	0.8	21

#	ARTICLE	IF	CITATIONS
109	The indications for the treatment of sarcoidosis: Wells Law. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2017, 34, 280-282.	0.2	21
110	Management of Advanced Pulmonary Sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 495-506.	2.5	21
111	Placenta-derived mesenchymal-like cells (PDA-001) as therapy for chronic pulmonary sarcoidosis: a phase 1 study. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2015, 32, 106-14.	0.2	21
112	The National Institutes of Health Blueprint for Neuroscience Research. Journal of Neuroscience, 2006, 26, 10329-10331.	1.7	20
113	Clinical management of pulmonary sarcoidosis. Expert Review of Respiratory Medicine, 2016, 10, 577-591.	1.0	20
114	Advanced Pulmonary Sarcoidosis. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 700-715.	0.8	20
115	Cholinergic Innervation in Cerebral Cortex. Cerebral Cortex, 1987, , 129-160.	0.6	18
116	Risk and outcome of COVID-19 infection in sarcoidosis patients: results of a self-reporting questionnaire. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2020, 37, e2020009.	0.2	18
117	Geoepidemiological big data approach to sarcoidosis: geographical and ethnic determinants. Clinical and Experimental Rheumatology, 2019, 37, 1052-1064.	0.4	18
118	A ventrodorsal GABA gradient in the embryonic retina prior to expression of glutamate decarboxylase. Neuroscience, 1997, 79, 863-869.	1.1	17
119	Therapy for Extrapulmonary Sarcoidosis. Seminars in Respiratory and Critical Care Medicine, 2002, 23, 589-596.	0.8	17
120	First patient-centred set of outcomes for pulmonary sarcoidosis: a multicentre initiative. BMJ Open Respiratory Research, 2019, 6, e000394.	1.2	17
121	Decreased phosphatidylcholine in the lung fluid of patients with sarcoidosis. Lipids, 1985, 20, 496-499.	0.7	16
122	Evaluating the Minimal Clinically Important Difference of the King's Sarcoidosis Questionnaire in a Multicenter Prospective Study. Annals of the American Thoracic Society, 2021, 18, 477-485.	1.5	16
123	COVID-19 and Sarcoidosis, Readiness for Vaccination: Challenges and Opportunities. Frontiers in Medicine, 2021, 8, 672028.	1.2	16
124	The six-minute walk test in sarcoidosis associated pulmonary hypertension: Results from an international registry. Respiratory Medicine, 2022, 196, 106801.	1.3	15
125	The challenge of translational research—a perspective from the NINDS. Nature Neuroscience, 2002, 5, 1029-1030.	7.1	14
126	Diagnosis of ventilator-associated pneumonia. Microbes and Infection, 2005, 7, 262-267.	1.0	14

#	ARTICLE	IF	CITATIONS
127	Projections to the pontine nuclei from choline acetyltransferase-like immunoreactive neurons in the brainstem of the cat. <i>Journal of Comparative Neurology</i> , 1990, 300, 183-195.	0.9	12
128	Unsupervised Clustering Reveals Sarcoidosis Phenotypes Marked by a Reduction in Lymphocytes Relate to Increased Inflammatory Activity on 18FDG-PET/CT. <i>Frontiers in Medicine</i> , 2021, 8, 595077.	1.2	12
129	Muscarinic M3 receptors inhibit a leak conductance in rat corticocollousal neurons. <i>NeuroReport</i> , 1992, 3, 889-892.	0.6	11
130	Management of repository corticotrophin injection therapy for pulmonary sarcoidosis: a Delphi study. <i>European Respiratory Review</i> , 2020, 29, 190147.	3.0	11
131	Surfactant Replacement for Ventilator-Associated Pneumonia: A Preliminary Report. <i>Respiration</i> , 2002, 69, 57-62.	1.2	10
132	Steroids for sarcoidosis: How much and for how long?. <i>Respiratory Medicine</i> , 2018, 138, S5-S6.	1.3	9
133	Assessment of dyspnea in sarcoidosis using the Baseline Dyspnea Index (BDI) and the Transition Dyspnea Index (TDI). <i>Respiratory Medicine</i> , 2022, 191, 106436.	1.3	9
134	Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis: A Narrative Review. <i>Pulmonary Therapy</i> , 2022, 8, 43-55.	1.1	9
135	Antibiotic resistance in the intensive care unit. <i>Current Opinion in Critical Care</i> , 2002, 8, 430-434.	1.6	8
136	Biologic and advanced immunomodulating therapeutic options for sarcoidosis: a clinical update. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 179-210.	1.3	8
137	Infection prevention in sarcoidosis: proposal for vaccination and prophylactic therapy. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2020, 37, 87-98.	0.2	8
138	Use of third-line therapies in advanced sarcoidosis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 834-840.	0.4	8
139	Accuracy of Serial PET-CT Imaging in Systemic Sarcoidosis. <i>Journal of Clinical Imaging Science</i> , 2014, 4, 21.	0.4	7
140	Sarcoidosis patient with lupus pernio and infliximab-induced myositis: Response to Acthar gel. <i>Respiratory Medicine Case Reports</i> , 2016, 17, 5-7.	0.2	7
141	Chest high-resolution computed tomography can make higher accurate stages for thoracic sarcoidosis than X-ray. <i>BMC Pulmonary Medicine</i> , 2022, 22, 146.	0.8	7
142	Immunosuppressant Therapy for Idiopathic Pulmonary Fibrosis. <i>BioDrugs</i> , 1996, 6, 431-442.	0.7	6
143	Methotrexate in sarcoidosis: hematologic and hepatic toxicity encountered in a large cohort over a six year period. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2020, 37, e2020001.	0.2	6
144	Can persistent tumor necrosis factor release lead to refractory sarcoidosis?. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2002, 19, 164-6.	0.2	6

#	ARTICLE	IF	CITATIONS
145	Microbiologic Diagnosis of Ventilator-Associated Pneumonia. Clinics in Chest Medicine, 2005, 26, 81-86.	0.8	5
146	Sarcoidosis. Clinics in Dermatology, 2007, 25, 231.	0.8	5
147	Results of the standard set for pulmonary sarcoidosis: feasibility and multicentre outcomes. ERJ Open Research, 2019, 5, 00094-2019.	1.1	5
148	Current treatment of sarcoidosis. Current Opinion in Pulmonary Medicine, 2020, 26, 591-597.	1.2	5
149	Management of immunosuppressants in the era of coronavirus disease-2019. Current Opinion in Pulmonary Medicine, 2021, 27, 176-183.	1.2	5
150	Nonbronchoscopic evaluation of ventilator-associated pneumonia. Seminars in Respiratory Infections, 2003, 18, 95-102.	1.3	5
151	Interpretation of the Wright-Giemsa Stained Bronchoalveolar Lavage Specimen. Laboratory Medicine, 2004, 35, 553-557.	0.8	4
152	Considerations in the Choice and Administration of Agents for Empiric Antimicrobial Therapy. Surgical Infections, 2005, 6, s-71-s-82.	0.7	4
153	Sarcoidosis. Clinics in Chest Medicine, 2015, 36, xv.	0.8	4
154	Summary for Clinicians: Clinical Practice Guideline for the Diagnosis and Detection of Sarcoidosis. Annals of the American Thoracic Society, 2020, 17, 1510-1515.	1.5	4
155	The Value of a Patient Global Assessment in Management of Sarcoidosis. Lung, 2021, 199, 357-362.	1.4	4
156	The Cholinergic System in the Chicken Retina: Cellular Localization and Development. , 1979, , 421-431.		4
157	A composite score to assess treatment response in pulmonary sarcoidosis: the Sarcoidosis Treatment Score (STS). Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2019, 36, 86-88.	0.2	4
158	Roflumilast (DalirespÂ®) to reduce acute pulmonary events in fibrotic sarcoidosis: a multi-center, double blind, placebo controlled, randomized clinical trial. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2021, 38, e2021035.	0.2	4
159	Sarcoidosis. Seminars in Respiratory and Critical Care Medicine, 2010, 31, 373-374.	0.8	3
160	Treatment of sarcoidosis-associated pulmonary hypertension: so close, andÂyet so far. European Respiratory Journal, 2017, 50, 1701725.	3.1	3
161	Higher Priced Older Pharmaceuticals. Chest, 2018, 153, 23-33.	0.4	3
162	Sarcoidosis: is cryobiopsy not cool enough? â€“ Authors' reply. Lancet Respiratory Medicine,the, 2018, 6, e45.	5.2	3

#	ARTICLE	IF	CITATIONS
163	Symptoms, impacts, and suitability of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT [®] , [©]) questionnaire in patients with sarcoidosis-associated pulmonary hypertension (SAPH): a qualitative interview study. <i>BMC Pulmonary Medicine</i> , 2021, 21, 365.	0.8	3
164	Extrapulmonary Sarcoidosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2002, 23, 503-504.	0.8	2
165	Sarcoidosis, Fatigue, and Sleep Apnea. <i>Chest</i> , 2013, 144, 1976-1977.	0.4	2
166	Circulatory TGF-beta1 is significantly higher in early stage of pulmonary sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2018, 35, 213-217.	0.2	2
167	Presence of onconeural antibodies in sarcoidosis patients with parasarcoidosis syndrome. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2019, 36, 254-260.	0.2	2
168	COVID-19 infections in sarcoidosis: a prospective single center study of 886 sarcoidosis patients. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2021, 38, e2021029.	0.2	2
169	The association of baseline sarcoidosis measurements with 6-month outcomes that are of interest to patients: Results from the On-line Sarcoidosis Assessment Platform Study (OSAP). <i>Respiratory Medicine</i> , 2022, 196, 106819.	1.3	2
170	Scout - sarcoidosis outcomes taskforce. A systematic review of outcomes to inform the development of a core outcome set for pulmonary sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2021, 38, e2021034.	0.2	2
171	Echocardiographic estimate of pulmonary artery pressure in sarcoidosis patients - real world data from a multi-national study.. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2022, 38, e2021032.	0.2	2
172	Novel antigenic determinant expressed in neurons of the dorsolateral hypothalamus in rat and human. <i>Journal of Neuroscience Research</i> , 1992, 31, 715-723.	1.3	1
173	Sarcoidosis update. <i>Current Opinion in Pulmonary Medicine</i> , 2017, 23, 432.	1.2	1
174	Cardiac sarcoidosis: worse pulmonary function due to left ventricular ejection fraction?. <i>Medicine (United States)</i> , 2019, 98, e18037.	0.4	1
175	Mixed Obstructive and Restrictive Ventilatory Defect in Sarcoidosis. <i>Chest</i> , 2020, 158, 1816-1817.	0.4	1
176	Chest CT scan: The best predictor of mortality in advanced pulmonary sarcoidosis?. <i>Respiratory Medicine</i> , 2020, 170, 106059.	1.3	1
177	Advances in predicting patient survival in pulmonary sarcoidosis. <i>Expert Opinion on Orphan Drugs</i> , 2021, 9, 113-122.	0.5	1
178	Detection of early phenotype cardiac sarcoidosis by cardiovascular magnetic resonance. <i>Current Opinion in Pulmonary Medicine</i> , 2021, 27, 478-483.	1.2	1
179	Diagnosis of Pneumonia in Immunocompromised Patient. , 0, , 53-93.		1
180	Sarcoidosis-Associated Pulmonary Hypertension: Diagnosis and Treatment. <i>Advances in Pulmonary Hypertension</i> , 2015, 14, 138-144.	0.1	1

#	ARTICLE	IF	CITATIONS
181	Inter-rater reliability of cutaneous sarcoidosis assessment tools via remote photographic assessment. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2017, 34, 165-169.	0.2	1
182	Preface. <i>Clinics in Chest Medicine</i> , 2008, 29, xiii-xiv.	0.8	0
183	Response. <i>Chest</i> , 2015, 147, e65-e66.	0.4	0
184	Response. <i>Chest</i> , 2018, 153, 1507-1508.	0.4	0
185	Sarcoidosis: Advances in Therapy. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 605-606.	0.8	0
186	Reply to P. B. et al., to Fahim and Rosewarne, and to Reich. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1322-1324.	2.5	0
187	Development of Cholinergic and Amino Acid Neurotransmitter Systems in the Chick Retina. <i>Cell and Developmental Biology of the Eye</i> , 1982, , 47-56.	0.1	0
188	Development of Cholinergic and Amino Acid Neurotransmitter Systems in the Chick Retina. <i>Cell and Developmental Biology of the Eye</i> , 1982, , 47-56.	0.1	0
189	Considerations in the choice and administration of agents for empiric antimicrobial therapy. <i>Surgical Infections</i> , 2005, 6 Suppl 2, S-71-82.	0.7	0
190	The lung in autoimmune diseases: sarcoidosis. <i>Handbook of Systemic Autoimmune Diseases</i> , 2022, , 169-188.	0.1	0
191	World Association for Sarcoidosis and Other Granulomatous Disease (WASOG) Centers of Excellence.. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2022, 38, e2021051.	0.2	0